Education
About Us
Working with TipRanks
Follow Us
PAION AG (DE:PA8)
FRANKFURT:PA8
PA8 Stock Chart & Stats
€0.01
€0.02(4.35%)
At close: 4:00 PM EDT
€0.01
€0.02(4.35%)
Day’s Range― - ―
52-Week Range€0.00 - €0.06
Previous CloseN/A
Volume5.28K
Average Volume (3M)6.23K
Market Cap
€92.74K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta8.70
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,133,699
10 Day Avg. Volume1,523
30 Day Avg. Volume6,230
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PA8 FAQ
What was PAION AG’s price range in the past 12 months?
PAION AG lowest stock price was €0.00 and its highest was €0.06 in the past 12 months.
What is PAION AG’s market cap?
PAION AG’s market cap is €92.74K.
When is PAION AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PAION AG’s earnings last quarter?
Currently, no data Available
Is PAION AG overvalued?
According to Wall Street analysts PAION AG’s price is currently Overvalued.
Does PAION AG pay dividends?
PAION AG does not currently pay dividends.
What is PAION AG’s EPS estimate?
PAION AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PAION AG have?
PAION AG has 7,133,699 shares outstanding.
What happened to PAION AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PAION AG?
Currently, no hedge funds are holding shares in DE:PA8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PAION AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
PAION AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.